---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-252180"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2022-09-27T23:59:59+00:00"
generated_at: "2026-06-23T07:15:19.647722+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# 4D Molecular Therapeutics appoints Noriyuki Kasahara to Board, promotes Fred Kamal to President and COO

## Summary
- Appointed Noriyuki Kasahara, M.D., Ph.D., to Board as Class I director and Chair of Science and Technology Committee.
- Promoted Fred Kamal, Ph.D., to President and COO; base salary increased to $475,000, annual target bonus 45%.
- Granted Kasahara option for 45,000 shares at $8.06; Kamal granted option for 15,000 shares at $8.06.
- Kasahara is Professor at UCSF with 30+ years in gene therapy, author of 150+ articles, inventor on 18 patents.

## SEC filing metadata
- accession: 0001193125-22-252180
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2022-09-27T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/d404270d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-252180
- JSON: https://secwatch.observer/filing/0001193125-22-252180.json
- Plain text: https://secwatch.observer/filing/0001193125-22-252180.txt

## Key facts
- Executive change
  Fred Kamal changed role as President and Chief Operating Officer at 4D Molecular Therapeutics, Inc..
  - Action: promoted
  - Role: President and Chief Operating Officer
  source text: appointed Fred Kamal, Ph.D., the Company’s current Chief Operating Officer and Chief Technical Officer, as President and Chief Operating Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm
- Executive change
  Noriyuki Kasahara was appointed as Class I director at 4D Molecular Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: appointed Noriyuki Kasahara, M.D., Ph.D., to the Board as a Class I director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650648/000119312522252180/0001193125-22-252180-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.